Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade
Hidenori Toyoda(Ogaki Municipal Hospital), Philip J. Johnson(Prince of Wales Hospital), Paul B.S. Lai(Chinese University of Hong Kong), Nóra Schweitzer(Medizinische Hochschule Hannover), James O’Beirne(The Honourable Society of Lincoln's Inn), Charing C. N. Chong(National University of Singapore), Takashi Kumada(Gifu Kyoritsu University), Mercedes Iñarrairaegui(University of Cambridge), Stephen L. Chan(Chinese University of Hong Kong), Toshifumi Tada(Himeji Red Cross Hospital), Derek Manas, Arndt Vogel(Princess Margaret Cancer Centre), Helen L. Reeves(Newcastle upon Tyne Hospital), Bruno Sangro(Clinica Universidad de Navarra), Sarah Berhane(University Hospitals Birmingham NHS Foundation Trust), Anthony W.H. Chan(Chinese University of Hong Kong), Frankie Mo(Chinese University of Hong Kong), Richard Fox(Cancer Research UK Clinical Trials Unit), Winnie Yeo(Chinese University of Hong Kong)
Cited by 177
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k